<DOC>
	<DOCNO>NCT02073812</DOCNO>
	<brief_summary>RPX7009 ( beta-lactamase inhibitor ) study combination carbapenem ( RPX2014 ) treat bacterial infection , include due multi-drug resistant bacteria .</brief_summary>
	<brief_title>Evaluating Plasma , Epithelial Lining , Alveolar Macrophage Concentrations Intravenous Carbavance™ ( RPX2014/RPX7009 ) Healthy Adult Subjects</brief_title>
	<detailed_description>The worldwide spread resistance antibiotic among Gram-negative bacteria , particularly member ESKAPE group pathogen , result crisis treatment hospital acquire infection . In particular , recent dissemination serine carbapenemase ( e.g. , KPC ) Enterobacteriaceae US hospital pose considerable threat carbapenems member beta-lactam class antimicrobial agent . Rempex develop fix combination antibiotic carbapenem ( RPX2014 ) plus new beta-lactamase inhibitor ( RPX7009 ) activity serine beta-lactamase , include KPC . This Phase 1 study ass pharmacokinetics intravenous RPX2014 RPX7009 plasma epithelial fluid .</detailed_description>
	<criteria>1 . Healthy adult male and/or female , 18 55 year age ( inclusive ) time screen . 2 . Body mass index ( BMI ) ≥ 18.5 ≤ 30 ( kg/m2 ) weight 55.0 100.0 kg ( inclusive ) time screen . 3 . Medically healthy clinically insignificant screen result ( e.g. , laboratory profile , medical history , electrocardiogram ( ECGs ) , physical examination ) deem PI . 4 . Nontobacco/nicotinecontaining product user minimum 6 month prior Day 1 . 5 . Voluntarily consent participate study . 1 . History presence significant oncologic , cardiovascular , pulmonary , hepatic , renal , hematological , gastrointestinal , endocrine , immunologic , dermatologic , neurological , psychiatric disease . 2 . Positive urine drug/alcohol test screening ( Day 1 ) . 3 . Positive test human immunodeficiency virus ( HIV ) hepatitis B surface antigen ( HBsAg ) . 4 . History presence alcoholism drug abuse within 2 year prior Day 1 . 5 . Hypersensitivity idiosyncratic reaction betalactam antibiotic ( e.g . penicillin , cephalosporin , carbapenems , etc. ) . 6 . Clinically significant pulmonary disease prevents subject undergoing bronchoscopy bronchopulmonary lavage . 7 . History seizure ( e.g. , epilepsy ) , head injury meningitis require ongoing antiseizure medication . 8 . Use prescription medication ( exception hormonal contraceptive hormone replacement therapy female ) within 14 day prior Day 1 . 9 . Participation another investigational clinical trial within 30 day prior Day 1 . 10 . Females pregnant lactating . 11 . Surgery within past three month prior Day 1 determine PI clinically relevant . 12 . Any acute illness include clinically significant infection within 30 day prior Day 1 . 13 . QTcF interval &gt; 450 msec , history prolong QT syndrome screening ( Day 1 ) . 14 . Calculated creatinine clearance le 80 mL/min ( CockroftGault method ) screening . 15 . Subjects clinically significant abnormality laboratory value screen ( Day 1 ) , include : 1 . White blood cell count ( WBC ) &lt; 3,000/mm3 , hemoglobin &lt; 11g/dL . 2 . Absolute neutrophil count &lt; 1,200/mm3 platelet count &lt; 120,000/mm3 . 16 . Liver function abnormality screen ( Day 1 ) ( define elevation bilirubin , AST ALT 1.5 x ULN normal range subject base age sex ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>